Calliditas closes acquisition of a controlling interest in Genkyotex SA
Calliditas Therapeutics AB (publ) (“Calliditas”) (Nasdaq OMX – CALTX; NASDAQ – CALT) today announced the closing of the acquisition of 62.7% of Genkyotex SA (“Genkyotex”) (Euronext Paris & Brussels: FR0013399474 – GKTX) in an off-market transaction.On August 13, 2020, Calliditas announced that it had entered into an agreement to acquire 7,236,515 ordinary shares of Genkyotex from Genkyotex’s largest shareholders and management team (the “Block Sellers”), representing 62.7% of the share capital and voting rights. Having now received clearance from the French Minister of Economy and Finance